Term
|
Definition
|
|
Term
| Breakdown (%) of cell cycle |
|
Definition
|
|
Term
| Two classes of drugs that act only on specific phases of cell cycle |
|
Definition
Plant alkaloids
DNA synthesis inhibitors |
|
|
Term
| Part of cell cycle where plant alkaloids work |
|
Definition
|
|
Term
| Part of cell cycle where DNA synthesis inhibitors work |
|
Definition
|
|
Term
| Cell cycle specific drugs kill proliferating or nonproliferating cells? |
|
Definition
|
|
Term
| Cell cycle non-specific drugs kill proliferating or nonproliferating cells? |
|
Definition
|
|
Term
| Cell cycle specific drugs are schedule or dose dependent? |
|
Definition
|
|
Term
| Cell cycle non-specific drugs are schedule or dose dependent? |
|
Definition
|
|
Term
| 4 main categories of cell cycle specific agents |
|
Definition
Plant alkaloids
Antibiotics
Alkylating agents
Antimetabolites |
|
|
Term
| List plant alkaloids and mechanism |
|
Definition
Etoposide (topoisomerase II inhibitor)
Camptothecins (irinotecan, topotecan) topoisomerase I inhibitor
Taxanes (microtubule stabilizer)
Vinca alkaloids (microtubule destabilizer) |
|
|
Term
| List cell cycle specific antibiotics and mechanism |
|
Definition
Bleomycin (DNA intercalation)
Epothilones (microtubule stabilizer) |
|
|
Term
| List the cell-cycle specific alkylating agent and mechanism |
|
Definition
| Procarbazine (DNA alkylation, mostly on newly synthesized DNA |
|
|
Term
| Where do antimetabolites work and general mechanism |
|
Definition
S-phase
Interfere with cell's ability to process new DNA) |
|
|
Term
|
Definition
5-FU
Capecitabine
6-MP
6-TG
Cladribine
Ara-C
Fludarabine
Gemcitabine
Leucovorin
Methotrexate
Pemetrexed
Hydroxyurea |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Ribonucleotide reductase inhibitor |
|
|
Term
| List categories of non-cell cycle specific alkylating agents |
|
Definition
Nitrogen mustard
Nitrosureas
Miscellaneous (busulfan, dacarbazine, procarbazine, temozolomide) |
|
|
Term
| List non-cell cycle specific nitrogen mustards |
|
Definition
Clorambucil
Cyclophosphamide
Ifosfamide
Mechlorethamine
Melphalan |
|
|
Term
| List non-cell cycle specific nitrosureas |
|
Definition
CCNU (lomustine)
BCNU (carmustine) |
|
|
Term
| List the non-cell cycle specific antibiotic |
|
Definition
|
|
Term
| What part of cell cycle do steroids work? |
|
Definition
|
|
Term
| Virtually all drugs induce myelosuppression except ______ |
|
Definition
|
|
Term
| List drugs that are vesicants (7) |
|
Definition
Alkylating agents
Mitomycin
Vinca alkaloids
Anthracyclines
Mechlorethamine
Carmustine
Dactinomycin |
|
|
Term
| Treatment for vinca alkaloid extravasation |
|
Definition
Topical heat
SQ hyaluronidase |
|
|
Term
| Treatment for taxane extravasation |
|
Definition
Topical cold
SQ hyaluronidase |
|
|
Term
| Treatment for anthracycline extravasation |
|
Definition
Topical cold
IV dextazoxane |
|
|
Term
| Treatment for mechlorethamine extravasation |
|
Definition
Topical cold
SQ sodium thiosulfate |
|
|
Term
| Treatment for platinum extravasation |
|
Definition
|
|
Term
| Drugs most likely to cause CNS toxicity |
|
Definition
Most alkylators (except cyclophosphamide)
Antimetabolites (gemcitabine, Ara-C, methotrexate)
Erlotinib, lapatinib |
|
|
Term
| Chemotherapy-induced neuropathy is primarily sensory/motor? |
|
Definition
|
|
Term
| Drugs most likely to cause neuropathy (5) |
|
Definition
Taxanes
Epothilones
Platinums
Vincristine
Bortezomib |
|
|
Term
| Drugs that cause complete alopecia (7) |
|
Definition
Taxanes
Epothilones
Topoisomerase I inhibitors (irinotecan, topotecan)
Anthracyclines (all)
Alkylators (esp. cyclophosphamide)
Dactinomycin
Bleomycin |
|
|
Term
| Drugs that cause permanent infertility (4) |
|
Definition
Vinblastine
Alkylators (virtually all)
Cisplatin
Melphalan |
|
|
Term
| Risk of secondary malignancies with etoposide, teniposide (topoisomerase II inhibitors) |
|
Definition
Mixed lineage leukemia, 11q23 rearrangement
Mean latency 2-3 years after stopping treatment |
|
|
Term
| Risk of secondary malignancy with alkylators |
|
Definition
AML M1/M2
MDS 5q- 7q-
5-7 year latency |
|
|
Term
| Risk of secondary malignancy with anthracyclines |
|
Definition
AML M1/M2
MDS 5q- 7q-
5-7 latency |
|
|
Term
| Toxicity reversal for methotrexate |
|
Definition
Leucovorin
Glucarpidase (Carboxypeptidase G) |
|
|
Term
| 5-FU toxicity reversal (non DPD deficient patient) |
|
Definition
|
|
Term
| 5-FU toxicity reversal (DPD deficient patient) |
|
Definition
|
|
Term
| Irinotecan treatment reversal UGT1A1 polymorphism |
|
Definition
Azathioprine (thiopurine methyltransferase)
Dose reduction with subsequent cycles |
|
|
Term
| Tamoxifen toxicity reversal |
|
Definition
|
|
Term
| Drug categories requiring renal monitoring and/or adjustment of dose (4) |
|
Definition
All platinums
All antimetabolites
Alkylators
Other (etoposide, topotecan, bleomycin, mitomycin) |
|
|
Term
| Major metabolism enzyme cyclophosphamide |
|
Definition
|
|
Term
| Major metabolism enzyme paclitaxel |
|
Definition
|
|
Term
| Major metabolism enzyme warfarin |
|
Definition
|
|
Term
| Major metabolism enzyme tamoxifen |
|
Definition
|
|
Term
| Major metabolism enzyme codeine |
|
Definition
|
|
Term
| Major metabolism enzyme irinotecan |
|
Definition
|
|
Term
| Major metabolism enzyme 5-FU |
|
Definition
|
|
Term
| Major metabolism enzyme gemcitabine |
|
Definition
|
|
Term
| Major metabolism enzyme Ara-C |
|
Definition
|
|
Term
| Likely alkylator increasing INR |
|
Definition
|
|
Term
| Antimetabolites increasing INR |
|
Definition
Capecitabine
5-FU
Gemcitabine
Methotrexate |
|
|
Term
| Likely anthracycline increasing INR |
|
Definition
|
|
Term
| Targeted agents increasing INR |
|
Definition
TKIs (imatinib, sorafenib, nilotinib)
EGFR inhibitors (erlotinib, gefitinib) |
|
|
Term
| Do vinca alkaloids increase INR? |
|
Definition
|
|
Term
| Taxane likely increasing INR |
|
Definition
|
|
Term
| HDAC inhibitor likely increasing INR |
|
Definition
|
|
Term
| Strategy if antacids required with erlotinib |
|
Definition
Change to sucralfate
Administer 8 hours later |
|
|
Term
Agents affected by food, AUC increases
Toxicity increase/decrease? |
|
Definition
Erlotinib
Gefitinib
Nilotinib
Lapatinib
Toxicity increases |
|
|
Term
Agents affected by food, AUC decreases
Efficacy increase/decrease? |
|
Definition
Afatinib
Efficacy decreases |
|
|
Term
| Common CYP3A4 inducers/inhibitors |
|
Definition
Antifungals, especially ketoconazole
Grapefruit juice
Herbals (St. Johns wort)
Antibiotics (Rifampicin) |
|
|
Term
| What happens with NSAIDs and methotrexate (renal function) |
|
Definition
| Impairs clearance of methotrexate, concentration of methotrexate increases |
|
|
Term
| What happens with renal failure/third spacing and methotrexate? |
|
Definition
Volume of distribution increases
Concentration of methotrexate increases |
|
|
